1 Understanding motivations of older women

2 to continue or discontinue breast cancer screening

3 **Short Title:** Breast cancer screening preferences of older women

4

- 5 Susan C. Weller, PhD,^{1,2,3,*} Monique R. Pappadis, PhD,^{1,3,4} Shilpa Krishnan, PhD,⁵
- 6 Marsja R. Stearnes, PhD,³ Kristin M. Sheffield, PhD, ^{3,6,7} Alai Tan, MD, PhD, ⁸ Jeffrey Z.
- 7 Qi,⁹ James S. Goodwin, MD. ^{3,10}

8

- ⁹ ¹ Department of Population Health and Health Disparities, School of Public and
- 10 Population Health, University of Texas Medical Branch (UTMB), Galveston, TX 77555;
- ¹¹ ² Department of Family Medicine, School of Medicine; UTMB;
- ¹² ³ Sealy Center on Aging, UTMB;
- ⁴ Department of Occupational Therapy, School of Health Professions, UTMB;

⁵ Department of Rehabilitation Medicine, Division of Physical Therapy, Emory

- 15 University, School of Medicine; Atlanta, GA, USA
- ⁶ Department of Surgery, School of Medicine, UTMB;
- ¹⁷ ⁷Global Medical Affairs, Eli Lilly and Company, Indianapolis, IN 46285;
- ⁸ College of Nursing, Ohio State University, Columbus, OH 43210;
- ⁹ Harvard College, Faculty of Arts and Sciences, Harvard University;
- ¹⁰ Department of Internal Medicine, UTMB.
- All contributors were employed by the University of Texas Medical Branch at the time
- this work was conducted.

- 24 *Corresponding Author:
- 25 Email: sweller@utmb.edu
- 26 Word Count: 252 Abstract, 3062 text, 4 Tables

27 ABSTRACT

- **Background**: Breast cancer screening guidelines indicate screening in women over 75
- 29 years of age is optional, depending upon patient health and preferences.
- 30 **Objectives:** To link experiences and perceptions of older women concerning screening
- to their intention to continue or discontinue screening.
- 32 **Design**: Qualitative comparative study, comparing continuers and discontinuers.
- 33 **Setting:** Community-residing adults.
- 34 **Participants:** A purposive sample (n=59) with equal representation of White, Black, and
- Hispanic women by age (70-74 years and 75 and older) and educational level (\leq 12
- 36 grade and >12 grade).
- 37 Measurements: In-depth qualitative interviews explored women's perceptions of
- 38 mammograms, the benefits and risks of screening, and personal screening
- 39 experiences. Interviews were coded and quality-checked by two or more coders. A
- 40 qualitative comparative analysis (QCA) was used to identify combinations of personal
- 41 characteristics and themes linked to the intention to continue (n=32) or discontinue

42 (n=27) screening.

Results: Personal experience themes were strongly linked to the intention to continue or discontinue. Women who mentioned recent screening (within three years) and either a spontaneously mentioned cancer story concerning a friend or family member or a doctor's screening recommendation intended to continue screening (91% true positive rate, model sensitivity). Women who did not schedule screening and who did not mention a cancer story or a doctor's recommendation (or neither) intended to

- discontinue screening (81% true negative rate, model specificity). These themes
- 50 transcended differences in race/ethnicity, age, and educational level.
- 51 **Conclusion:** Continuation of breast cancer screening in older women is motivated by
- 52 their personal screening history combined with cancer experiences and/or a doctor's
- 53 screening recommendation.
- 54
- 55 Key words: Mammography, breast cancer screening, older women, geriatrics,
- 56 qualitative comparative analysis

57 **INTRODUCTION**

Breast cancer screening guidelines have converged on the age when women should 58 start breast cancer screening, but ambiguity remains concerning when to stop. The US 59 Preventive Services Task Force (USPSTF) recently broadened the age for screening, 60 adding women 40-49 years of age, and now recommends screening for women 40-74 61 years of age, noting insufficient evidence of a benefit in women 75 and older.¹ The 62 American Cancer Society (ACS) and the American College of Obstetricians and 63 Gynecologists (ACOG) recommend screening beginning at 40 and continuing while 64 women are in good health with a life expectancy of 10 or more years.²⁻⁴ Screening of 65 women who are older or have limited life expectancy can expose them to unnecessary 66 treatment that may not prolong their life.⁵⁻⁷ By age 80, the average woman's life 67 expectancy is less than 10 years⁸ suggesting that discontinuation of screening would be 68 appropriate. However, the receptivity of older women to discontinuation of screening is 69 unclear, since half of women older than 75⁹ and many women with limited expectancy 70 continue to be screened.^{10,11} To facilitate discussions with older women about 71 screening, this paper explores women's rationales for continuation and discontinuation 72 73 of breast cancer screening.

74

Breast cancer incidence increases with older age and is highest in women 65 and older. Incidence peaks for women in their 70s, then decreases slightly, but remains high until their mid-80s.¹² Mortality due to breast cancer increases steadily with older age,¹³ but can be reduced with mammography screening for breast cancers. Clinical trials demonstrate that screening reduces breast cancer mortality 14% in women 50-59

years, 33% in those 60-69 years, and 20% in women 70-74 years of age.¹⁴ Although
incidence remains high for women aged 75 and older, no one in that age range was
enrolled in the clinical trials – thus, there is no evidence for or against the effectiveness
of mammography screening for women aged 75 and older.

84

Screening declines from almost three-quarters of women under 75 reporting screening 85 to half of women over 75 reporting screening.⁹ For women in their 70s, shared decision-86 making between doctor and patient can help guide the decision to continue or 87 discontinue screening.¹⁻³ Informed and shared decision-making are patient-centered 88 practices that inform patients about options and possible outcomes to help them make 89 choices that best match their preferences.¹⁵⁻¹⁷ A patient-centered perspective is 90 particularly important for breast cancer screening in older women because 91 mammography may have a net benefit for some patients but not others and because 92 older women may assign different values to the benefits and risks of screening.18,19 93 94 Studies suggest that women care more about early detection of cancer than about the negative aspects of screening, such as detection of cancers that would not affect 95 mortality.^{20,21} Although some older women may insist on continuing breast cancer 96 screening,²²⁻²⁴ screening decisions may be influenced by a doctor's recommendation, 97 personal screening history, and the reassurance that screening may offer.^{22,25-27} 98 99

This study explores factors associated with the decision to continue or discontinue screening in women in the age range where discontinuation tends to occur (70 and older). However, this study departs from previous descriptive studies of positive and

negative aspects of mammogram screening and screening preferences by instead 103 identifying combinations of key factors that predict the intention to continue or 104 discontinue screening. A qualitative comparative analysis (QCA)^{28,29} of in-depth 105 interviews identified themes and combinations of themes uniquely linked to continuation 106 or discontinuation of breast cancer screening. QCA is *similar to* logistic regression, 107 108 bridging gualitative and guantitative analyses, but is based on set and subset relations rather than guantitative measures or probability.³⁰ A strength of QCA is its ability to 109 identify complex interactions with small sample sizes, allowing for asymmetry in 110 prediction, in case the factors predicting continuation differ from those predicting 111 discontinuation. Specifically, this study explored older women's perceptions of breast 112 cancer screening, to discover whether the decision to continue screening is driven 113 primarily by a physician's recommendation and if not, what other factors contribute to a 114 woman's screening intention. 115

116

117 METHODS

This study was part of a larger project examining older women's motivations for
screening, their willingness to discontinue screening,²⁴ their understanding of
overdiagnosis,³¹ and their preferences for communication about screening,³² but
departs from prior studies in attempting to identify the pathway between experiences
and the intention to screen.

Participants. Women 70 years and older with no prior history of breast cancer were
 recruited from a local geriatric clinic, senior community living facilities, senior public
 housing, local community centers, and churches in southeast Texas. Because of

disparities in screening,³³⁻³⁵ a purposive sample was sought with equal representation 126 across age, race/ethnicity, and educational level.³⁶ Approximately five women were 127 selected from each of the 12 categories formed by younger-old/older-old ages (70-74 128 vs. 75+), lower/higher education (<12 vs. >12 grade), and race/ethnicity (White, Black, 129 Hispanic). The sample size was adequate as a sample size of 5 can capture ideas with 130 131 a 30% or higher population prevalence and a sample of 16 (combining subgroups) can capture ideas with a 10% or higher population prevalence (with 80% confidence);³⁷ a 132 comparison of ideas and themes from continuers and discontinuers aggregated across 133 demographic subgroups would ensure capturing the most salient ideas and themes.³⁸ 134 The study was approved by the University's Institutional Review Board; participants 135 provided oral informed consent (audiotaped) and received a \$25 gift card for their time. 136 Women were recruited between 8/27/13 and 3/26/18. This study integrates their data 137 with a new analysis. 138

139

Procedure. Women were asked a series of open-ended questions about mammogram
screening (See Supplement, Table A). A first set of questions covered general
information about mammograms: their description, purpose, benefits, and risks. A
second set of questions explored the decision process. All interviews were audiotaped,
transcribed, and coded.

145

Analysis. Themes were identified by repetitions within and across transcripts.³⁹ For
 each substantive theme, the interviewer (MS) did the first coding and drafted a
 codebook in NVivo 10.⁴⁰ Then, a second and third person (MRP, SK) independently

coded themes, and team members (MS, AT, SW, MRP, SK) reviewed transcripts for 149 codes relevant to each theme and iteratively revised the codebook. Codes were quality-150 checked via content analysis of transcripts using specific keywords and phrases 151 ("keywords in context")⁴¹ with review and validation by team members. Content for the 152 decision process (who initiated screening, did the doctor recommend screening, 153 154 mention of a personal cancer story, mention of screening reminders, and whether screening will be continued) was described by codes and guotes. 155 156 157 To see if narratives of women intending to continue screening differed from those who did not, the salience of each theme/code was estimated within each group and a 158

159 qualitative comparative analysis (QCA) was conducted to identify key factors in the

decision pathway to continuation/discontinuation. Responses of each woman were

161 represented in a spreadsheet as a dichotomous profile representing the

presence/absence of themes mentioned when talking about mammograms. Theme

salience for discontinuers/continuers was estimated with the proportion in each group

164 mentioning each theme/code^{38,41,42} and compared with a chi square test.⁴³

165

QCA identified key factors ("prime implicants")⁴¹ linked to the intention to screen by comparing the profiles of thematic code usage of individuals intending to continue or discontinue. QCA^{28-30,41} considers all possible combinations of codes and logical relationships are used to link thematic codes to group membership (implemented in Tosmana⁴⁴). QCA uses formal Boolean logic (set and subset relations) to identify important distinguishing factors between subgroups. For example, if (1) all women

(young and old) with a doctor's recommendation wanted to continue screening and (2)
all women (young and old) without a doctor's recommendation wanted to discontinue
screening, then a doctor's recommendation distinguishes continuers from discontinuers,
while age does not.

176

177 **RESULTS**

Sample Characteristics. Fifty-nine English-speaking women were interviewed for this 178 study: 28 were 70-74 years old and 31 were 75 and older; 24 were White, 21 Black, and 179 180 14 Hispanic; and 29 had lower and 30 had higher educational levels. Although the sampling target was for five women in each subcategory, some categories (e.g., older 181 Hispanics with higher educational levels) were difficult to locate and some were slightly 182 over-represented (e.g., White women with higher educational levels). Most women were 183 recruited from community settings and very few rated their health poorly. The interviews 184 lasted between 45 to 60 minutes. 185

186

Intention to Continue or Discontinue Screening. Approximately half of the women 187 188 (n=32) expressed an intention to continue screening and half (n=27) did not. Those who were unsure about continuing (n=1) and those who stated their intention to follow their 189 doctor's recommendation to discontinue screening (n=4) were coded as discontinuers. 190 191 Those who reported they would follow their doctor's recommendation to continue screening were considered continuers (n=2). The decision to continue/discontinue 192 screening was associated with older age (67% of discontinuers vs. 41% of continuers, 193 194 p<.05), but not education or race/ethnicity (Table 1).

196

197 TABLE 1: DEMOGRAPHIC CHARACTERISTICS BY SCREENING INTENT

	DISCONTINUE	CONTINUE
	(n=27)	(n=32)
Demographics		
Age (75+ yrs)*	67% (18/27)	41% (13/32)
Education (> High School)	48% (13/27)	53% (17/32)
Race/Ethnicity		
White	44% (12/27)	38% (12/32)
African-American	33% (9/27)	38% (12/32)
Hispanic	22% (6/27)	25% (8/32)
Community Recruitment	86% (19/22)	90% (26/29)
Self-Rated Health (very poor)	7% (2/27)	0% (0/32)

198 199

200

Many women said they would continue screening as long as they lived ("*As long as I live*," "*I guess until I die*," or "*As long as I am able*") or that they did not intend to stop ("*I would not consider stopping*" or "*I don't intend to stop*"). Some linked continuation to a doctor's recommendation, for example: "*Probably indefinitely unless the doctor would cut me off and say that it's not necessary any longer.*"

206

207 Discontinuation was expressed simply as "*I figure I'm through having them*," often linked

to advanced age: "*I'm* 83 years old and I don't feel like I really need one," or "I probably

209 won't have one next year, just because I don't think it's necessary for somebody 76

210 years old next year, and I've never had any problems at all," or to a doctor's

recommendation in the context of age, "The suggestion was when I first started out to
get them annually, and then later. I don't remember exactly when we moved it forward,
and then after 60, probably five years. Then I have nothing after maybe 70, and I
haven't had any."

215

General Descriptions, Purpose, Benefits, and Risks of Mammograms. Most of the 216 women were very familiar with mammograms. Only two women had never had one and 217 one additional woman said that she had one, but described a screening procedure that 218 may have been an MRI. Narratives concerning mammogram descriptions, purpose, 219 benefits, and risks were fairly consistent across age, educational, and racial/ethnic 220 groups with few meaningful differences between discontinuers and continuers (Table 2). 221 Women described mammograms as an X-ray or machine; an image, picture, or photo of 222 the breast; or more generally as a test, exam, check, or screen of the breast. The 223 224 purpose was to detect cancer; detect lumps or nodes; or detect abnormalities. Benefits were to detect cancer (themes describing the purpose of screening often were repeated 225 and emphasized), to detect lumps/nodes/abnormalities; to detect problems early to get 226 227 timely treatment; to live longer; and to gain health reassurance. Some reported that mammograms had no risk, while others reported risk due to radiation exposure. 228 229 Pain/discomfort was reported as a risk, as was the possibility of an inaccurate reading. 230 Only two of the 15 codes appeared to differ in salience between discontinuers and continuers. Discontinuers were somewhat more likely to describe mammograms as a 231 232 "breast X-ray" (56% vs. 35%, p<.18) and cite the benefit of "cancer detection" (48% vs. 233 28%, p<.20).

234

236 TABLE 2: MAMMOGRAM CHARACTERISTICS AND THEMATIC CODES BY INTENT TO CONTINUE SCREENING

Theme, code (examples)	DISCONTINUE	CONTINUE
Description		
Breast X-ray ("It's an X-ray of your breasts.")	56% (15/27)	36% (11/31)
Breast exam (" <i>test of the breast</i> ")	26% (7/27)	23% (7/31)
Breast image ("when they do the image of the breast")	22% (6/27)	32% (10/31)
Purpose		
Detect cancer ("To find out whether you have cancer.")	62% (16/26)	66% (21/32)
Detect lump ("To see if you have any growths or detect lumps that shouldn't be there.")	42% (11/26)	28% (9/32)
Detect abnormality ("To detect tumors or abnormalities in the tissue.")	19% (5/26)	19% (6/32)
Benefits		
Detect cancer ("Test of the breast to make sure there's no cancer cells or cancer.")	48% (13/27)	28% (9/32)
Detect lump/abnormality ("To detect any abnormalities in your breast.")	26% (7/27)	31% (10/32)
Timely treatment ("to catch it early" or "catch it in time")	26% (7/27)	38% (12/32)
Health Reassurance ("To tell if you're alright or if you're not")	22% (6/27)	25% (8/32)
Live longer ("keep myself healthy and alive for my children")	7% (2/27)	9% (3/32)
Risks		
No risk ("I never heard of any risks")	26% (7/27)	38% (12/32)
Radiation/cancerous ("The possibility of getting cancer from the X-ray.")	30% (8/27)	22% (7/32)
Pain or discomfort ("women don't like to be squeezed. They always said it hurts so hard.")	22% (6/27)	19% (6/32)
Inaccurate reading ("False readings" or "mistakes")	15% (4/27)	6% (2/32)

238	Decision Proces	s for Screening	. Discussions	about the s	creening proces	s revealed
-----	------------------------	-----------------	---------------	-------------	-----------------	------------

- personal experiences that were more strongly linked to the intention to
- 240 continue/discontinue screening than were general descriptions of mammograms,
- including the purpose, benefits, and risks of mammograms. Self-initiation of screening
- appointments, having a doctor's recommendation, recent screening (<3 years), and
- spontaneous mention of a cancer story involving a friend or family member showed
- large, statistically significant differences in salience between the two groups (Table 3).

246 TABLE 3: DECISION PROCESS THEMATIC CODES BY INTENT TO CONTINUE SCREENING

Theme, code (<i>examples</i>)	DISCONTINUE	CONTINUE
Decision Process		
Doctor initiated screening		
("It's usually set-up with my primary care that she'll tell me, 'this year you'll go for eye, or		
bone density, or mammogram,' you know, and I just know that it'sI go every spring, and		
that's it.")	74% (20/27)	69% (22/32)
Self-Initiated screening*		
("Sometimes I remind my doctor that it's time.")	7% (2/27)	31% (10/32)
Reminder		
("I just got the letter last month I think it was.")	19% (5/27)	22% (7/32)
Personal cancer story**		
("There is breast cancer in my family," or "…on my father's side of the family there's been all kinds of cancers.")	33% (9/27)	75% (24/32)
Doctor recommended screening (verbally) **		
("My doctor is the one that says," or, "I just went along with it.")	19% (5/27)	69% (22/32)
Recent screening, screening within past three years**		
	41% (11/27)	91% (29/32)

* p< .05, ** p< .001

Women described the initiation of screening as doctor-initiated, self-initiated, or both. 250 Those who intended to continue screening were more likely to report self-initiation of 251 screening appointments (31% vs. 7%, p<.05). Although it was expected that 252 screening might be influenced by a doctor scheduling an appointment or by a call/letter 253 reminder, only a doctor's verbal recommendation influenced intent. A doctor's 254 255 recommendation was reported much more often by those who intended to continue screening (69% vs. 19%, p<.001). Those who desired to continue screening were more 256 likely to have *had a recent mammogram* (91% vs. 41%, p<.001) and were more likely 257 to spontaneously mention a cancer story involving family or friends (75% vs. 33%, 258 p<.001). 259

260

Themes Linked to the Decision to Continue. Of the 21 thematic codes (Tables 2 and 261 3) and three demographic characteristics (age, race/ethnicity, educational level), only 262 263 five factors were associated with the intent to continue screening: younger age, reporting a cancer story involving family or friends, self-initiation of screening, recent 264 screening, and receiving a doctor's recommendation (Supplement, Table B). Of the 32 265 266 possible combinations of the presence/absence of the five factors, only 19 occurred in the 59 cases and only four of the themes (excluding age) were linked to the intention to 267 continue/discontinue. Table 4 shows the 19 combinations of the factors that occurred in 268 269 the 59 narratives, the case counts for each distinct profile of themes, and the classification rules linked to continuation/discontinuation. For example, there were 15 270 271 women who reported a personal cancer story (+), a doctor's recommendation (+), and 272 recent screening (+); 14 (6+7+1) wanted to continue and 1 to discontinue.

273

274 TABLE 4: PROFILES FOR ALL 59 CASES & PREDICTION RULES

	Older Age	Initiated Screen	Cancer Story	Dr. Recom	Recent Screen	Continue # Cases (n=32)	Discontinue # Cases (n=27)
	E RULE#1: reen + Can	cer Story +	Doctor's	Recomme	endation		
	+	-	+	+	+	6	1
	-	-	+	+	+	7	0
	-	+	+	+	+	1	0
	E RULE#2: reen + Can	cer Storv -	No Docto	r's Recom	mendatio	n	
	+	+	+	-	+	5	0
	-	+	+	-	+	2	0
	+	-	+	-	+	1	1
CONTINU Recent Sc	E#3: creen + Doc	tor's Recon	nmendatio	on - No Ca	ancer Stor		1
	-	+	-	+	+	1	0
	+	+	-	+	+	0	1
	-	-	-	+	+	6	0
					1		-
	+	-	-	+	+	0	2
	NUE RULE	#1:	er Story -			nmendation	
		#1:	- :er Story - -		or's Recon	nmendation	6
	NUE RULE	#1:	- :er Story - - -			nmendation 0 0	6 3
	NUE RULE: d Screenin +	#1: g - No Canc	-	No Docto	or's Recon	nmendation 0 0 0	6 3 2
	NUE RULE: d Screenin +	#1: g - No Canc	-	No Docto	pr's Recon	nmendation 0 0	6 3
No Initiate	NUE RULE: d Screenin +	#1: g - No Canc - - - - - - - -	- - -	No Docto	or's Recon - + - +	mmendation 0 0 0 0	6 3 2
No Initiate	NUE RULE: d Screenin + + - - NUE RULE:	#1: g - No Canc - - - - - - - -	- - -	No Docto	or's Recon - + - +	mmendation 0 0 0 0	6 3 2
No Initiate	NUE RULE ed Screenin + - - NUE RULE ed Screenin	#1: g - No Canc - - - - - - - -	- - -	No Doctor's	or's Recon - + - + Recomm	nmendation 0 0 0 0 0 endation	6 3 2 3
No Initiate DISCONTI No Initiate DISCONTI	NUE RULE d Screenin + - - NUE RULE d Screenin + - NUE RULE	#1: g - No Canc - - - #2: g - No Canc g - No Canc - - -	- - - - :er Story + -	No Docto - - - - - - - - - - - - - - - - - - -	or's Recon - + - + s Recomm - -	mmendation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	6 3 2 3
No Initiate DISCONTI No Initiate DISCONTI	NUE RULE d Screenin + - - NUE RULE d Screenin + -	#1: g - No Canc - - - #2: g - No Canc g - No Canc - - -	- - - - :er Story + -	No Docto - - - - - - - - - - - - - - - - - - -	or's Recon - + - + s Recomm - -	mmendation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	6 3 2 3
No Initiate DISCONTI No Initiate DISCONTI	NUE RULE d Screenin + - NUE RULE d Screenin + - NUE RULE d Screenin	#1: g - No Canc - - - #2: g - No Canc g - No Canc - - -	- - - - - - - - - - - - - - - - - - -	No Docto - - - - - - - - - - - - - - - - - - -	or's Recon - + - + s Recomm - -	nmendation 0 0 0 0 0 0 0 0 0 0 0 endation 1 0	6 3 2 3 0 1
No Initiate DISCONTI No Initiate DISCONTI No Initiate	NUE RULE d Screenin + - NUE RULE d Screenin + - NUE RULE d Screenin + - NUE RULE -	#1: g - No Canc - - - #2: g - No Canc g - No Canc - - -	- - - - - - Story - No +	No Docto - - - - - - - - - - - - - - - - - - -	or's Recon - + - + s Recomm - -	mmendation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	6 3 2 3 0 1
No Initiate DISCONTI No Initiate DISCONTI	NUE RULE d Screenin + - NUE RULE d Screenin + - NUE RULE d Screenin + - NUE RULE -	#1: g - No Canc - - - #2: g - No Canc g - No Canc - - -	- - - - - - Story - No +	No Docto - - - - - - - - - - - - - - - - - - -	or's Recon - + - + s Recomm - -	mmendation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	6 3 2 3 0 1

²⁷⁵

276

277 The intention to continue screening was motivated by recent screening, a cancer

experience, and a doctor's recommendation, regardless of age. Women with all *three* of

these factors intended to continue (Rule #1). All continuers had a recent mammogram
screening, but it was not sufficient to predict continued screening. The power of a
personal cancer experience (Rule #2) *or* a doctor's recommendation to continue
screening (Rule #3) was clear as women of all demographic groups were motivated to
continue screening if they had recent screening *and* either a cancer story or a doctor's
recommendation or both. These three factors correctly classified 29/32 cases desiring
to continue (91% true positives).

286

287 Similarly, the intention to discontinue was characterized by the absence of a cancer story, absence of a doctor's recommendation, and the absence of self-initiated 288 screening (Rule #4). All who intended to discontinue had not self-initiated screening in 289 the past, although they may or may not have been recently screened. Failure to self-290 initiate screening combined with the absence of a doctor's recommendation (Rule #5) 291 292 and/or a personal cancer story/experience (Rule #6) predicted intent to discontinue. A doctor's recommendation to screen was ignored by women who did not self-initiate 293 screening and had no motivating personal cancer story. These factors correctly 294 295 classified 22/27 cases desiring to discontinue (81% true negatives). One profile (two women who self-initiated screening, reported a cancer story, but did not have a doctor's 296 297 recommendation; bottom, Table 4) remained unaccounted for (one woman wanted to 298 continue and one wanted to discontinue). Since a classification rule accommodating this profile would count as either a correct continuation and an error for discontinuation or 299 300 vice versa, we simply counted it as an error against both continuation and 301 discontinuation predictions.

302

303 **DISCUSSION**

Few studies describe the breast cancer screening preferences of older women, and 304 those that do rarely link specific attributes and themes to actual screening or the 305 intention to screen.^{27,45-49} This is the first study to directly link themes to the intention to 306 307 screen. Themes identified in this study are similar to those identified in other studies,^{22,25,46} but in addition to listing salient themes, here we identified combinations of 308 themes explicitly motivating the intention to continue or discontinue screening in older 309 310 women. Continued screening is primarily a function of past screening behavior (recent screening), but past screening must be combined with a personal cancer experience 311 and/or a doctor's verbal recommendation to motivate future screening. Women who 312 have been recently screened and who have had a friend or family member with cancer 313 are likely to continue to screen with or without a doctor's recommendation. For women 314 315 who have been screened but who do not know someone with cancer, a doctor's recommendation is the tipping point for continuing screening. While other studies on 316 women in their 70s identified the importance of a doctor's recommendation,²⁶ this study 317 318 shows a doctor's recommendation to get screened only activates future screening when combined with recent screening. 319

320

Discontinuation of screening is similarly a function of past screening, but discontinuation is determined by whether a woman has self-initiated screening rather than whether she was recently screened. Women who did not self-initiate their screening appointments and who have not known someone with cancer and/or do not have a doctor's

recommendation are likely to discontinue screening. If a doctor does not give a
recommendation for screening and the doctor's office or health care system does not
schedule screening, screening is likely to be discontinued. A woman can override this
passive discontinuation option, however, by scheduling her own appointment, especially
if she has known someone with cancer. Often, discontinuation of breast cancer
screening seems to follow a passive path.

331

The role of older age in the decision to discontinue has been unclear. Some assume that older age may be a consideration for patients, as mammogram screening declines with age (with large decreases occurring at 75 and 80 years).^{9,50} However, older age has not been directly linked to a desire to discontinue.²⁵ Older-old women in this study were more likely to express a desire to discontinue, but results indicated that other factors played more important roles in a woman's decision to continue or discontinue screening than simply older age.

339

Women in this study were generally healthy, as few rated their health as poor. Poor selfrated health is linked to higher mortality^{51,52} and the two women who rated their health as poor intended to discontinue screening. There were no systematic racial/ethnic or educational differences in narratives linked to the intention to continue/discontinue breast cancer screening. These findings parallel those from a national survey that did not find race, age, or health status differences in utilization.⁴⁹

346

Women in this study also were fairly well-informed about breast cancer screening. All 347 women were able to describe a mammogram and its purpose. Previous studies 348 described harms and risks of screening mammography, including possible unnecessary 349 diagnostic procedures, costs, complications, as well as pain and anxiety.^{1,18} In this 350 study, women reported pain, possible radiation risk, and the possibility of inaccurate 351 352 results, but not risk from unnecessary treatment. Furthermore, these perceived risks did not motivate their decision to continue or discontinue. Risks of mammogram screening 353 354 are sometimes cited as reasons to discontinue screening, but women appear to prioritize detection of cancer over potential risks.^{18,25,53} Thus, screening may offer the 355 benefit of health reassurance ("better to know" or "peace of mind").^{20,25,53} However, in 356 this study the effects of perceived risks and benefits were surpassed by a personal 357 cancer story, a story that may express a perceived higher personal risk for cancer. 358 Experiences of friends and family may lead women to overestimate breast cancer 359 360 incidence, mortality, and the predictive value of mammography – and thus, overestimate their own personal risk of being diagnosed with and dying from breast cancer.^{18,54} 361 362

Physicians are an important source of information on screening and affect patient uptake of screening.^{22,26,49} In older women who have been recently screened, a provider can influence the decision to screen.^{25,47} This study supports the idea that a tipping point in the decision for many older women may be the recommendation – or lack of a recommendation – to get screened. Cessation may be a harder decision than continuing and discussion of cessation may even compromise patient-provider trust,²³ but a simple reduction in reminders may reduce overuse in older patients.²⁵

370

A limitation of this study is the possible inaccuracy in recollections of past behaviors and 371 reports on future intentions. Women may decide what they want to do and then report 372 information that supports that action. For example, a woman who wants to be screened 373 may be more likely to remember and report that her doctor recommended it. Also, 374 375 women were not followed prospectively to verify their intentions, although intention is a strong predictor of behavior and can serve as a proxy for actual behavior.⁴⁷ Another 376 limitation is that the study was based on a small regional sample and, as for most 377 378 gualitative studies, results are suggestive and not definitive. In-depth exploration allows for the identification of new ideas and processes that need to be validated with an 379 independent, representative sample. However, the replication of many themes in this 380 study with those in prior studies^{22,25,27,46,47} adds evidence toward the validity of our 381 findings. 382

383

A strength of the study was that QCA facilitated the understanding of complex 384 relationships among factors linked to the intention to screen, winnowing down almost 385 386 two dozen themes to a less than a handful. QCA bridges gualitative and guantitative approaches by combining qualitative data with a systematic analysis of cases.⁵⁵ 387 However, results can be sensitive to the selection of explanatory variables or the 388 389 addition of more cases. Our analysis focused on the five factors that maximally discriminated continuers and discontinuers and, although QCA estimates a causal 390 391 model, our models did not incorporate temporal relationships, as the outcome variable 392 was intention to screen and not prospectively verified behavior. Never-the-less, QCA

suggests the path between themes, experiences, and perceptions to the intention tocontinue or discontinue screening.

395

QCA offers a way to interpret patterns in gualitative data that is systematic and 396 transparent. Our analysis systematically compared narratives of women expressing a 397 398 desire to continue with those who might discontinue and estimated true positive and true negative classification rates for each group. QCA results, however, may not be 399 400 unique: there may be more than one set of rules to account for response patterns. 401 Classification of cases can be complicated and the trade-off is a more complex set of rules with greater accuracy versus a more parsimonious solution with reduced 402 accuracy. Here, a few cases were counted as errors, when they could have been 403 accommodated with extra classification rules. Thus, we opted for fewer rules that 404 slightly reduced the true negative rate. 405

406

Conclusion. Among the many positive and negative aspects of screening, only a few
tend to motivate older women to continue or discontinue breast cancer screening.
Foremost is their past screening behavior. Then, intentions are motivated by a personal
cancer experience in a friend or relative and/or a doctor's recommendation. Some may
be ready to discontinue, especially those who delay or skip reminders, and may be most
influenced by a discussion with their physician about continuing or discontinuing
screening.

414

415

416 **ACKNOWLEDGEMENTS**

- 417 **Funding Sources:** This work was supported by US federal grants from AHRQ (R24
- 418 HS022134 to JSG), NIH (K05 CA134923 to JSG; P30 AG024832 to Elena Volpi), and
- 419 NIDILRR (90AR5009 to Kenneth J. Ottenbacher).

422	REFERENCES
423 424	1. U. S. Preventive Services Task Force, Nicholson WK, Silverstein M, et al. Screening
425	for Breast Cancer: US Preventive Services Task Force Recommendation Statement.
426	JAMA. Apr 30 2024;doi:10.1001/jama.2024.5534
427	2. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at
428	Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. Oct
429	20 2015;314(15):1599-614. doi:10.1001/jama.2015.12783
430	3. American Cancer Society. American Cancer Society Recommendations for the Early
431	Detection of Breast Cancer. https://www.cancer.org/cancer/types/breast-
432	cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-
433	for-the-early-detection-of-breast-cancer.html.
434	4. American College of Obstetricians and Gynecologists. Practice Bulletin Number 179:
435	Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstet
436	<i>Gynecol</i> . Jul 2017;130(1):e1-e16. doi:10.1097/AOG.000000000002158
437	5. Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-Cancer Tumor Size,
438	Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med. Oct 13
439	2016;375(15):1438-1447. doi:10.1056/NEJMoa1600249

- 6. Advani S, Abraham L, Buist DSM, et al. Breast biopsy patterns and findings among
- older women undergoing screening mammography: The role of age and comorbidity. J
- 442 *Geriatr Oncol.* Mar 2022;13(2):161-169. doi:10.1016/j.jgo.2021.11.013
- 443 7. Tan A, Kuo YF, Goodwin JS. Potential overuse of screening mammography and its
- 444 association with access to primary care. *Med Care*. Jun 2014;52(6):490-5.
- 445 doi:10.1097/MLR.00000000000115
- 446 8. Social Security. Period Life Table, 2021, as used in the 2024 Trustees Report.
- 447 <u>https://www.ssa.gov/oact/STATS/table4c6.html</u>
- 9. National Center for Health Statistics. Table 33. Use of mammography among women
- aged 40 and over. Hyattsville, MD. *Health, United States, 2018.* 2018;
- 450 10. Schonberg MA, Breslau ES, McCarthy EP. Targeting of mammography screening
- 451 according to life expectancy in women aged 75 and older. J Am Geriatr Soc. Mar
- 452 2013;61(3):388-95. doi:10.1111/jgs.12123
- 11. Freedman RA, Keating NL, Pace LE, Lii J, McCarthy EP, Schonberg MA. Use of
- 454 Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy.
- 455 *J Clin Oncol*. Sep 20 2017;35(27):3123-3130. doi:10.1200/JCO.2016.72.1209
- 456 12. Surveillance Epidemiology and End Results Program. Breast: SEER incidence rates
 457 by age at diagnosis, 2016-2020, by sex, delay-adjusted SEER incidence rate, all

- 458 races/ethnicities. National Cancer Institute. Accessed Sept 5, 2024,
- 459 https://seer.cancer.gov/statistics-
- 460 <u>network/explorer/application.html?site=55&data_type=1&graph_type=3&compareBy=se</u>
- 461 <u>x&chk_sex_3=3&rate_type=2&race=1&advopt_precision=1&advopt_show_ci=on&hdn_</u>
- 462 <u>view=0#resultsRegion0</u>.
- 13. Surveillance Epidemiology and End Results Program. Breast: US mortality rates by
- age at death, 2016-2020, by sex, all races/ethnicities. National Cancer Institute.
- 465 Accessed Sept 5, 2024, <u>https://seer.cancer.gov/statistics-</u>
- 466 <u>network/explorer/application.html?site=55&data_type=2&graph_type=3&compareBy=se</u>
- 467 <u>x&chk_sex_3=3&race=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0#result</u>
 468 <u>sRegion0.</u>
- 469 14. Nelson HD, Cantor A, Humphrey L, et al. Screening for Breast Cancer: A
- 470 Systematic Review to Update the 2009 U.S. Preventive Services Task Force
- 471 *Recommendation*. Evidence Syntheses No 124. Rockville (MD): Agency for Healthcare
- 472 Research and Quality; 2016.
- 15. Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered
- 474 care. *N Engl J Med*. Mar 1 2012;366(9):780-1. doi:10.1056/NEJMp1109283
- 16. Rimer BK, Briss PA, Zeller PK, Chan EC, Woolf SH. Informed decision making:
- what is its role in cancer screening? *Cancer*. Sep 1 2004;101(5 Suppl):1214-28.
- 477 doi:10.1002/cncr.20512

- 17. Hersch JK, Nickel BL, Ghanouni A, Jansen J, McCaffery KJ. Improving
- 479 communication about cancer screening: moving towards informed decision making.
- 480 *Public Health Res Pract*. Jul 26 2017;27(2)doi:10.17061/phrp2731728
- 18. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast
- 482 cancer screening decisions. *JAMA*. Apr 2 2014;311(13):1327-35.
- 483 doi:10.1001/jama.2014.1398
- 19. Walter LC, Schonberg MA. Screening mammography in older women: a review.
- 485 JAMA. Apr 2 2014;311(13):1336-47. doi:10.1001/jama.2014.2834
- 486 20. Mathioudakis AG, Salakari M, Pylkkanen L, et al. Systematic review on women's
- values and preferences concerning breast cancer screening and diagnostic services.
- 488 *Psychooncology*. May 2019;28(5):939-947. doi:10.1002/pon.5041
- 489 21. Yu J, Nagler RH, Fowler EF, Kerlikowske K, Gollust SE. Women's Awareness and
- 490 Perceived Importance of the Harms and Benefits of Mammography Screening: Results
- 491 From a 2016 National Survey. *JAMA Intern Med.* Sep 1 2017;177(9):1381-1382.
- 492 doi:10.1001/jamainternmed.2017.2247

22. Schonberg MA, Ramanan RA, McCarthy EP, Marcantonio ER. Decision making and
counseling around mammography screening for women aged 80 or older. *J Gen Intern Med.* Sep 2006;21(9):979-85. doi:10.1111/j.1525-1497.2006.00487.x

496 23. Torke AM, Schwartz PH, Holtz LR, Montz K, Sachs GA. Older adults and forgoing

497 cancer screening: "I think it would be strange". *JAMA Intern Med*. Apr 8

498 2013;173(7):526-31. doi:10.1001/jamainternmed.2013.2903

499 24. Housten AJ, Pappadis MR, Krishnan S, et al. Resistance to discontinuing breast

500 cancer screening in older women: A qualitative study. *Psychooncology*. Jun

501 2018;27(6):1635-1641. doi:10.1002/pon.4708

502 25. Brotzman LE, Shelton RC, Austin JD, et al. "It's something I'll do until I die": A

⁵⁰³ qualitative examination into why older women in the U.S. continue screening

504 mammography. *Cancer Med*. Oct 2022;11(20):3854-3862. doi:10.1002/cam4.4758

26. Schonberg MA, McCarthy EP, York M, Davis RB, Marcantonio ER. Factors

influencing elderly women's mammography screening decisions: implications for

507 counseling. *BMC Geriatr*. Nov 16 2007;7:26. doi:10.1186/1471-2318-7-26

27. Eisinger F, Viguier J, Blay JY, et al. Uptake of breast cancer screening in women

aged over 75 years: a controversy to come? *Eur J Cancer Prev*. Jan 2011;20 Suppl

510 1:S13-5. doi:10.1097/01.cej.0000391564.03265.3f

28. Ragin CC, Mayer SE, Drass KA. Assessing Discrimination: A Boolean Approach. *American Sociological Review*. 1984;49(2):221-234. doi:10.2307/2095572

- 29. Rihoux B, De Meur G. Chapter 3: Crisp-Set Qualitative Comparative Analysis
- 514 (csQCA). In: Rihoux B, Ragin CC, eds. *Configurational Comparative Methods:*
- 515 *Qualitative Comparative Analysis (QCA) and Related Techniques.* Sage Publications;

516 **2009:33-68**.

- 30. Grofman B, Schneider CQ. An Introduction to Crisp Set QCA, with a Comparison to
- 518 Binary Logistic Regression. *Political Research Quarterly*. 2009;62(4):662-672.
- 519 doi:10.1177/1065912909338464
- 520 31. Pappadis MR, Volk RJ, Krishnan S, et al. Perceptions of overdetection of breast
- 521 cancer among women 70 years of age and older in the USA: a mixed-methods analysis.
- 522 *BMJ Open*. Jun 14 2018;8(6):e022138. doi:10.1136/bmjopen-2018-022138
- 32. Hoover DS, Pappadis MR, Housten AJ, et al. Preferences for Communicating about
- 524 Breast Cancer Screening Among Racially/Ethnically Diverse Older Women. *Health*
- 525 *Commun*. Jun 2019;34(7):702-706. doi:10.1080/10410236.2018.1431026
- 33. Bynum JP, Braunstein JB, Sharkey P, Haddad K, Wu AW. The influence of health
- 527 status, age, and race on screening mammography in elderly women. *Arch Intern Med.*
- 528 Oct 10 2005;165(18):2083-8. doi:10.1001/archinte.165.18.2083
- 529 34. Ahmed AT, Welch BT, Brinjikji W, et al. Racial Disparities in Screening
- 530 Mammography in the United States: A Systematic Review and Meta-analysis. *J Am Coll*
- 531 *Radiol*. Feb 2017;14(2):157-165 e9. doi:10.1016/j.jacr.2016.07.034

- 35. Monticciolo DL. Current guidelines and gaps in breast cancer screening. *J Am Coll*
- 533 *Radiol*. Oct 2020;17(10):1269-1275. doi:10.1016/j.jacr.2020.05.002
- 36. Johnson JC. *Selecting ethnographic informants*. Qualitative research methods.
- 535 Sage Publications; 1990:96 p.
- 536 37. Fugard AJB, Potts HWW. Supporting thinking on sample sizes for thematic
- analyses: a quantitative tool. International Journal of Social Research Methodology:
- 538 Theory & Practice. 2015;18(6):669–684. doi:10.1080/13645579.2015.1005453
- 38. Weller SC, Vickers B, Bernard HR, et al. Open-ended interview questions and
- saturation. *PLoS One*. 2018;13(6):e0198606. doi:10.1371/journal.pone.0198606
- 39. Ryan GW, Bernard HR. Techniques to Identify Themes. *Field Methods*.
- 542 2003;15(1):85-109. doi:10.1177/1525822X02239569
- 40. QSR International Pty Ltd. *NVivo 10 Qualitative Data Analysis Software*. Version 10.
 QSR International Pty Ltd; 2012.
- 41. Bernard HR, Ryan GW. *Analyzing Qualitative Data: Systematic Approaches*. SAGE
 Publications; 2009
- 42. Weller SC, Romney AK. *Systematic Data Collection, Qualitative Research Methods*.
 vol 10. Sage Publications; 1988.

43. SPSS Inc. SPSS. Chicago: SPSS Inc.; 1990.

- 44. Cronqvist L. *Tosmana*. Version 1.521. University of Trier, Germany; 2016.
- 551 <u>http://www.tosmana.net</u>
- 45. Pillay J, Guitard S, Rahman S, et al. Patient preferences for breast cancer
- screening: a systematic review update to inform recommendations by the Canadian
- Task Force on Preventive Health Care. *Syst Rev.* May 28 2024;13(1):140.
- 555 doi:10.1186/s13643-024-02539-8
- 46. Dickson-Swift V, Adams J, Spelten E, Blackberry I, Wilson C, Yuen E. Breast cancer
- screening motivation and behaviours of women aged over 75 years: a scoping review.
- 558 BMC Womens Health. Apr 24 2024;24(1):256. doi:10.1186/s12905-024-03094-z
- 47. Schoenborn NL, Gollust SE, Nagler RH, et al. Effect of Messaging on Support for
- 560 Breast Cancer Screening Cessation Among Older US Women: A Randomized Clinical
- 561 Trial. JAMA Netw Open. Aug 1 2024;7(8):e2428700.
- 562 doi:10.1001/jamanetworkopen.2024.28700
- 48. Smith J, Cvejic E, Houssami N, et al. Randomized Trial of Information for Older
- 564 Women About Cessation of Breast Cancer Screening Invitations. *J Gen Intern Med*. Jun
- 565 2024;39(8):1332-1341. doi:10.1007/s11606-024-08656-3

566	49. Fox SA, Siu AL, Stein JA. The importance of physician communication on breast
567	cancer screening of older women. Arch Intern Med. Sep 26 1994;154(18):2058-68.

568 50. Blustein J, Weiss LJ. The use of mammography by women aged 75 and older:

- factors related to health, functioning, and age. *J Am Geriatr Soc*. Aug 1998;46(8):941-6.
- 570 doi:10.1111/j.1532-5415.1998.tb02746.x
- 571 51. Idler EL, Angel RJ. Self-rated health and mortality in the NHANES-I Epidemiologic
- 572 Follow-up Study. *Am J Public Health*. Apr 1990;80(4):446-52. doi:10.2105/ajph.80.4.446
- 573 52. Benjamins MR, Hummer RA, Eberstein IW, Nam CB. Self-reported health and adult
- 574 mortality risk: an analysis of cause-specific mortality. Soc Sci Med. Sep

575 2004;59(6):1297-306. doi:10.1016/j.socscimed.2003.01.001

- 576 53. Collins K, Winslow M, Reed MW, et al. The views of older women towards
- 577 mammographic screening: a qualitative and quantitative study. Br J Cancer. May 11
- 578 2010;102(10):1461-7. doi:10.1038/sj.bjc.6605662
- 579 54. Hoffman RM, Lewis CL, Pignone MP, et al. Decision-making processes for breast,
- colorectal, and prostate cancer screening: the DECISIONS survey. *Med Decis Making*.
- 581 Sep-Oct 2010;30(5 Suppl):53S-64S. doi:10.1177/0272989X10378701

- 582 55. Rihoux B. Bridging the Gap Between the Qualitative and Quantitative Worlds? A
- 583 Retrospective and Prospective View on Qualitative Comparative Analysis. *Field*
- 584 *Methods*. 2003;15(6):351-365. doi:10.1177/1525822X03257690